Appointment dossier — Colon Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Colon Cancer
Compounds named in the cited literature for Colon Cancer, labeled by the strongest evidence found:
- BRAF V600E-targeted therapy — Named in the literature
- checkpoint inhibitors — Named in the literature
- colonic stenting — Named in the literature
- complete mesocolic excision (CME) — Named in the literature
- HER2-targeted therapy — Named in the literature
- standard high-quality right hemicolectomy — Named in the literature
- systemic therapy — Named in the literature
Open recruiting trials (18)
- NCT07140679 · Phase 2 — Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer (United States)
- NCT06731894 · Phase 2 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors (United States)
- NCT07410494 · Phase 1 / Phase 2 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (China)
- NCT07255729 — An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer (United States)
- NCT05696002 — Advanced Pelvic Surgical Oncology Database - Prospective Observational Study (United Kingdom)
- NCT03667170 · Phase 2 — KN035 for dMMR/MSI-H Advanced Solid Tumors (China)
- NCT05867251 · Phase 1 / Phase 2 — Study of AVZO-021 in Patients With Advanced Solid Tumors (United States)
- NCT05176483 · Phase 1 — Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (United States)
- NCT06400472 · Phase 1 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (United States)
- NCT05985954 · Phase 1 — Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy (United States)
- NCT06179160 · Phase 1 — A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (United States)
- NCT07524322 · Phase 1 — Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors (United States)
- NCT07470853 · Phase 1 — A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. (United States)
- NCT05768503 · Phase 3 — Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC (China)
- NCT04516681 · Phase 3 — Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer (China)
- NCT06856837 · Phase 2 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (Austria)
- NCT03539822 · Phase 1 / Phase 2 — Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (United States)
- NCT02584244 · Phase 1 / Phase 2 — Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers (United States)
Most-relevant first: trials that name Colon Cancer, then broader trials you may still qualify for. 1190 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT07140679), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?